<DOC>
	<DOC>NCT00567762</DOC>
	<brief_summary>To investigate the efficacy and safety of FK506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis</brief_summary>
	<brief_title>Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis</brief_title>
	<detailed_description>0.1% FK506 ophthalmic suspension were administered twice-a-day to patients with vernal keratoconjunctivitis in whom treatment with topical anti-allergic agents had been ineffective. The primary efficacy endpoint was the mean change from the baseline (before the treatment)in total score for objective clinical signs at the final observation. The safety of FK506 ophthalmic suspension was also investigated.</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Vernal keratoconjunctivitis patients diagnosed by "Guideline of diagnosis and treatment of allergic conjunctival disease" Patients with type I reactions defined by skin testing, antibody measurement, etc. Age over 6 years old Subjects receiving systemic administration or subconjunctival injection of corticosteroid or immunosuppressants(ophthalmic and systemic medications) within 2weeks of initiation of the study Subjects needed to wear contact lenses during treatment period on a testing eye Subjects complicating an eye infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Keratoconjunctivitis</keyword>
	<keyword>vernal keratoconjunctivitis</keyword>
	<keyword>FK506</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>